We receive funding from a variety of sources that recognize the value of our high-impact research.
A Ribozyme Rescue Strategy for Dry Age-Related Macular Degeneration. John Sullivan (Principal Investigator). VA Central Office. $330,000. 1/1/2025-12/1/2027.
“Research Career Scientist Award (GS-15)”. Steven Fliesler (Principal Investigator). Dept of Veterans Affairs (VA). $637,073. 10/1/2021-9/1/2026.
Epigenetic Architecture of the RPE and Choroid: Identification of Therapeutic Targets For AMD. Margaret DeAngelis (Principal Investigator). Macular Degeneration Foundation, Inc. $500,000. 5/1/2020-7/1/2025.
Ancestry Network for the human cell atlas in the eye. Margaret DeAngelis (Co-Principal Investigator). Chan-Zuckerberg Initiative. $536,859. 2/1/2022-1/1/2025.
Pediatric network for the human cell atlas in the eye. Margaret DeAngelis (Co-Principal Investigator). Chan-Zuckerberg. $517,500. 2/1/2022-1/1/2025.
A Ribozyme Rescue Strategy for Dry Age-Related Macular Degeneration. John Sullivan (Principal Investigator). Veterans Administration BLRD Merit Award. $715,000. 10/1/2009-12/1/2024.
Pediatric network for the human cell atlas in the eye (Peds RFA). John Lillvis (Co-Investigator). Chan Zuckerberg Initiative. $400,712. 10/1/2021-9/1/2024.
Clinical Translational Science Award (CTSA). Steven Fliesler (Co-Investigator). National Institutes of Health/NCATS. $22,698,278. 4/1/2019-3/1/2024.
Regulation of mRNA decay in retinal development and maintenance. Xiuqian Mu (Principal Investigator). National Eye Institute. $2,024,085. 4/1/2020-3/1/2024.
Immunotherapy for acute lung injury secondary to influenze. John Sullivan (Co-Investigator). National Heart Lung and Blood Institute. $1,747,088. 4/1/2020-3/1/2024.
ER stress and diabetic retinopathy. Sarah Zhang (Principal Investigator). NIH, NEI. 9/1/2010-2/1/2024.
Molecular Mechanisms of Severe Diabetic Retinopathy. Sarah Zhang (Principal Investigator). NIH. 2/1/2020-1/1/2024.
Molecular Mechanisms of Severe Diabetic Retinopathy. Joshua Jianxin Wang (Co-Investigator). NIH/NEI. 2/1/2020-1/1/2024.
Development of Enhanced Hammerhead Ribozymes (E-hhRzs) as Therapeutics for AMD and other Retinal Diseases. John Sullivan (Principal Investigator). JB McDonald Foundation, Evergreen CO Donald R. McJunkin, President. $15,000. 1/1/2022-12/1/2023.
Generation of a human cell neural retina atlas with single cell RNA Seq. Margaret DeAngelis (Co-Principal Investigator). Chan-Zuckerberg. $345,621. 10/1/2020-10/1/2023.
Epigenetic-guided studies of AMD pathology and iPSC-RPE transplantation therapy. Michael Farkas (Principal Investigator). Department of Veterans Affairs. 10/1/2019-9/1/2023.
“Ocular Sequelae and Intervention in a Rat Model of Blast Overpressure Polytrauma”. Steven Fliesler (Co-Principal Investigator). Dept of Veterans Affairs (VA). $682,781. 1/1/2019-9/1/2023.
Single nucleus chromatin accessibility and transcriptomic characterization of Age-related macular degeneration. Margaret DeAngelis (Principal Investigator). Genentech, Inc. $942,213. 6/1/2021-6/1/2023.
A Study of Estrogen and Body Mass Index in Fuchs’ Endothelial Corneal Dystrophy. Sangita Patel (Co-Investigator). NIH. $452,925. 7/1/2021-6/1/2023.
“Studies on the requirement of dolichol synthesis-dependent N-glycosylation during photoreceptor development: Insights into autosomal recessive retinitis pigmentosa-59”. Steven Fliesler (Principal Investigator). Knights Templar Eye Foundation. $70,000. 7/1/2021-6/1/2023.
